Literature DB >> 2825622

Treatment of experimental cytomegalovirus infections with acyclovir.

C A Bruggeman1, W Engels, J Endert.   

Abstract

Subcutaneous (s.c.) administration of Acyclovir (ACV) (100 mg/1 kg bodyweight) resulted in an ACV blood level of 80 microM at 2 h post infection. Thereafter the level declined rapidly reaching undetectable levels at 12 h post infection. Administration of pro-ACV (100 mg/kg body weight) by s.c. or intravenous (i.v.) route resulted in ACV levels of 75 microM and 160 microM respectively after 30 min. But here again the blood level of ACV declined rapidly and was completely disappeared after 12 h. Continuous administration of pro-ACV in daily doses of 100, 250 and 350 mg/kg body weight resulted in ACV blood levels of 15 microM, 19 microM and 39 microM, respectively. The effect of ACV and pro-ACV on the replication of CMV was measured in immunesuppressed rats. In rats inoculated with RCMV the daily administration of 25 to 50 mg ACV per kg body weight by s.c. injections twice daily, did not result in a reduction of virus titers in spleen and liver, but when the RCMV-infected rats were treated by 100 mg pro-ACV per kg body weight virus titers in the spleen and liver were significantly reduced as compared with those in sham-treated animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825622     DOI: 10.1007/BF01310731

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

Review 1.  Recent trends and development in antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

Review 2.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

Review 3.  Basic biochemical and pharmacological aspects of antiviral agents.

Authors:  W H Prusoff; M Zucker; W R Mancini; M J Otto; T S Lin; J J Lee
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

4.  The in vitro activity of acyclovir and related compounds against cytomegalovirus infections.

Authors:  A S Tyms; E M Scamans; H M Naim
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

Review 5.  The spectrum of antiviral activities of acyclovir in vitro and in vivo.

Authors:  P Collins
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

6.  Rat cytomegalovirus induces cellular purine and pyrimidine nucleoside kinases in rat embryo fibroblasts and TK- rat-2 cells. Correlations with the antiviral activity of Acyclovir.

Authors:  H Meijer; C A Bruggeman; P H Dormans; C P van Boven
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

7.  Passive transfer of cytomegalovirus by cardiac and renal organ transplants in a rat model.

Authors:  J H Bruning; C A Bruggeman; C P van Boven; P J van Breda Vriesman
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

8.  The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent.

Authors:  P Collins; D J Bauer
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

9.  Isolation of a cytomegalovirus-like agent from wild rats.

Authors:  C A Bruggeman; H Meijer; P H Dormans; W M Debie; G E Grauls; C P van Boven
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

10.  Cytomegaloviral infections in the guinea pig: experimental models for human disease.

Authors:  F J Bia; B P Griffith; C K Fong; G D Hsiung
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  1 in total

1.  Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.

Authors:  F S Hasnie; J Breuer; S Parker; V Wallace; J Blackbeard; I Lever; P R Kinchington; A H Dickenson; T Pheby; A S C Rice
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.